Marketing Authorization Applications, Quarterly Dividends, Publication of Clinical Trial Data, Acquisitions, and Financial

  Marketing Authorization Applications, Quarterly Dividends, Publication of
 Clinical Trial Data, Acquisitions, and Financial Results - Analyst Notes on
                Regeneron, Amgen, Sangamo, Alnylam, and Agios

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, March 11, 2014

NEW YORK, March 11, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Regeneron
Pharmaceuticals, Inc. (NASDAQ: REGN), Amgen, Inc. (NASDAQ: AMGN), Sangamo
BioSciences, Inc. (NASDAQ: SGMO), Alnylam Pharmaceuticals, Inc. (NASDAQ:
ALNY), and Agios Pharmaceuticals, Inc. (NASDAQ: AGIO). Private wealth members
receive these notes ahead of publication. To reserve complementary membership,
limited openings are available at:


Regeneron Pharmaceuticals, Inc. Analyst Notes

On March 3, 2014, Regeneron Pharmaceuticals, Inc. (Regeneron) announced that
Bayer Yakuhin, Ltd. (Bayer Yakuhin) - a subsidiary of Bayer HealthCare, has
submitted an application for marketing authorization for EYLEA (aflibercept)
Injection for the treatment of patients with diabetic macular edema (DME) to
the Japanese Ministry of Health, Labour and Welfare (MHLW). "Clinically
significant DME is a leading cause of vision loss in the working-age
population suffering from diabetes. With increasing rates of diabetes
worldwide, there continues to be a need for new treatment options," said
George D. Yancopoulos, M.D., Ph. D., Chief Scientific Officer of Regeneron and
President of Regeneron Laboratories. "We are pleased with this regulatory
submission and hope that if approved, EYLEA will provide a new option for the
treatment of DME in Japan." The full analyst notes on Regeneron
Pharmaceuticals, Inc. are available to download free of charge at:


Amgen, Inc. Analyst Notes

On March 5, 2014, Amgen, Inc. (Amgen) announced that its Board of Directors
has declared a dividend of $0.61 per share for Q2 2014. The Company informed
that the dividend is payable on June 6, 2014, to all stockholders of record as
of the close of business on May 15, 2014. The full analyst notes on Amgen,
Inc. are available to download free of charge at:


Sangamo BioSciences, Inc. Analyst Notes

On March 6, 2014, Sangamo BioSciences, Inc. (Sangamo) announced the
presentation of data from its SB-728-T program to develop a 'functional cure'
for HIV/AIDS at the Conference on Retroviruses and Opportunistic Infections
(CROI 2014). In addition, the Company informed that data from an earlier Phase
1 clinical study in this program was also published in the March 6, 2014 issue
of the New England Journal of Medicine (NEJM). "Our studies have generated
valuable data that will enable us to maximize the potential of this novel
immunologic therapy for HIV and help optimize patient selection and
treatment," said Geoff Nichol, M.B., Ch.B., Executive Vice President of
Research and Development at Sangamo. Edward Lanphier, President and CEO of the
Company, added, "In the next clinical trial of SB-728-T, which is expected to
begin in the first half of 2014, we will implement mRNA delivery of the ZFNs
to the cells, which will provide both process- and cost-saving advantages over
viral delivery as well as the potential to re-dose." The full analyst notes on
Sangamo BioSciences, Inc. are available to download free of charge at:


Alnylam Pharmaceuticals, Inc. Analyst Notes

On March 6, 2014, Alnylam Pharmaceuticals, Inc. (Alnylam) announced the
closing of the previously announced acquisition of Merck's wholly owned
subsidiary Sirna Therapeutics, Inc. (Sirna), post the expiration of the
Hart-Scott-Rodino waiting period. In consideration for the Sirna common stock,
Alnylam has paid Merck $25.0 million in cash and has agreed to issue to Merck
2.5 million shares of Alnylam common stock with a value of $150.0 million.
Commenting on this acquisition, John Maraganore, Ph.D., CEO of Alnylam said,
"Further, we believe our acquisition of Merck's RNAi assets and Sirna
subsidiary supports Alnylam's continued leadership on RNAi intellectual
property and delivery, including with GalNAc conjugate technology." The full
analyst notes on Alnylam Pharmaceuticals, Inc. are available to download free
of charge at:


Agios Pharmaceuticals, Inc. Analyst Notes

On March 6, 2014, Agios Pharmaceuticals, Inc. (Agios) reported its Q4 2013 and
full-year 2013 financial results. In Q4 2013, the Company's revenues totalled
$6.7 million, up 7.4% YoY, while full-year 2013 revenues totalled $25.5
million, up 1.8% YoY. Q4 2013 net loss applicable to common stockholders was
$12.4 million, or $0.40 loss per share, compared to a net loss of $7.1
million, or $2.09 loss per share, in Q4 2012. Full-year 2013 net loss
applicable to common stockholders was $43.6 million, or $2.83 loss per share,
compared to a net loss of $27.3 million, or $8.02 loss per share, for
full-year 2012. "In 2013, we continued to apply our scientific and clinical
leadership in the field of cellular metabolism towards our goal of
transforming the lives of patients with cancer and inborn errors of
metabolism," said David Schenkein, M.D., CEO of Agios. "We successfully filed
two investigational new drug applications, or INDs, for novel first-in-class
therapeutic candidates and completed IND activities for our third program. In
early 2014, we continue to make important progress across our pipeline." The
full analyst notes on Agios Pharmaceuticals, Inc. are available to download
free of charge at:


About Analysts Review
We provide our members with a simple and reliable way to leverage our economy
of scale. Most investors do not have time to track all publicly traded
companies, much less perform an in-depth review and analysis of the
complexities contained in each situation. That's where Analysts Review comes
in. We provide a single unified platform for investors' to hear about what
matters. Situation alerts, moving events, and upcoming opportunities.




  oThis is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
  oInformation in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
  oThis information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
  oIf you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at pubco [at]
  oFor any urgent concerns or inquiries, please contact us at compliance [at]
  oAre you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to research [at] for consideration.


Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Analysts Review. An
outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Analysts Review in this article or
report according to the Procedures outlined by Analysts Review. Analysts
Review is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.


Analysts Review makes no warranty, expressed or implied, as to the accuracy or
completeness or fitness for a purpose (investment or otherwise), of the
information provided in this document. This information is not to be construed
as personal financial advice. Readers are encouraged to consult their personal
financial advisor before making any decisions to buy, sell or hold any
securities mentioned herein.


Analysts Review is not responsible for any error which may be occasioned at
the time of printing of this document or any error, mistake or shortcoming. No
liability is accepted by Analysts Review whatsoever for any direct, indirect
or consequential loss arising from the use of this document. Analysts Review
expressly disclaims any fiduciary responsibility or liability for any
consequences, financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1) guarantee the
accuracy, timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The included
information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA

SOURCE Analysts Review

Contact: Adam Redford CONTACT PHONE: +852-8191-3972
Press spacebar to pause and continue. Press esc to stop.